Inversago Pharma Doses First Patient in Phase 2 Trial of INV-202, an Oral, Peripherally-acting CB1 Inverse Agonist, in Patients with Diabetic Kidney Disease – Yahoo Finance

Data from Phase 2 Clinical Trial May Also Provide Insights into Diabetes- and Obesity-related Complications
MONTREAL, November 29, 2022–(BUSINESS WIRE)–Inversago Pharma Inc. ("Inversago"), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD).
The Phase 2 trial of INV-202, a first-in-class, peripherally-acting CB1 inverse agonist, is a multi-centered, randomized, double-blind, placebo-controlled study that will evaluate the albumin to creatinine ratio in up to 240 adult subjects with type 1 and type 2 diabetes and DKD. Participants will receive once-daily oral doses of 10 or 25mg of INV-202 or placebo during the 16-week study. Additional trial information can be found at https://clinicaltrials.gov/ via the identifier NCT05514548.
This study builds on positive Phase 1b data that will be presented at a future scientific conference. It is also supported by evidence from pre-clinical data, first presented at the European Renal Association meeting in June, that showed strong reno-protective effects of INV-202 in a model of DKD. In addition, data suggest that INV-202 would have additive effects when added to standard of care.
"The initiation of this Phase 2 trial in DKD is a significant milestone in our development plan for INV-202," said Glenn Crater, MD, Chief Medical Officer at Inversago. "Peripheral CB1 blockade has the potential to address the significant unmet medical need in DKD as well as other complications of diabetes and obesity."
"We’re excited about the progress of our INV-202 program that represents a novel, orally administered option for treating metabolic conditions," said François Ravenelle, PhD, Chief Executive Officer at Inversago.
About INV-202
INV-202 is a small molecule CB1 inverse agonist being developed by Inversago for the potential treatment of a range of cardiometabolic and fibrotic conditions, including diabetic kidney disease. It is specifically designed to preferentially block CB1 receptors in peripheral tissues such as the kidneys, gastro-intestinal tract, liver, pancreas, adipose tissues, muscles, lungs and other organs. The therapeutic effects of a peripheral CB1 blockade in a range of cardiometabolic and fibrotic diseases are well-documented, paving the way for potential treatment of a large number of patients with current unmet needs.
About Diabetic Kidney Disease
DKD is a chronic progressive disease that accounts for more than 50% of end-stage renal disease cases world-wide. It occurs when diabetes causes damage to the glomeruli and proximal renal tubules that are essential to blood filtering and waste elimination. As a complication of type 1 and type 2 diabetes, diabetic nephropathy affects approximately 1 in 3 people living with diabetes in the United States. No cure exists for this indication and available medications only help slowing the progression of the disease. Like other chronic diseases, it is expected that multiple mechanisms are needed to achieve adequate control of this progressive disease. Inversago believes that peripheral CB1 blockade represents a promising therapeutic avenue for such a metabolic disorder.
About Inversago Pharma
Inversago Pharma is a privately owned, clinical stage, Canadian biotech company, specialized in the development of new therapies focusing on CB1 blockade, based on first-in-class, peripherally-acting CB1 inverse agonists. Inversago aims to provide new treatment options that improve the lives of patients affected by metabolic conditions such as diabetic kidney disease (DKD), including diabetic nephropathy (DN), type 1 and type 2 diabetes (T1D / T2D), non-alcoholic steatohepatitis (NASH), complications of obesity and hypertriglyceridemia (HTG), as well as fibrotic indications like progressive fibrosis-interstitial lung disease (PF-ILD), including idiopathic pulmonary fibrosis (IPF) and other conditions. For more information, visit inversago.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221129005239/en/
Contacts
Glenn S. Vraniak
Chief Financial Officer
Inversago Pharma Inc.
info@inversago.com
Media and Investors
Argot Partners
inversago@argotpartners.com
Arrowhead provided a bullish update for its midstage liver disease treatment on Monday, pushing ARWR stock to rocket Tuesday.
Shares of Novocure (NASDAQ: NVCR) were jumping 7.6% higher as of 10:42 a.m. ET on Tuesday. The nice gain came after the company announced that Health Canada approved Optune for treating newly diagnosed and recurrent glioblastoma (GBM), an aggressive form of brain cancer. Canada represents a significant market opportunity for Novocure.
The new stores will occupy approximately 3,000 square feet, less than a third of the size of a standard Rite Aid Pharmacy.
Eisai plans to share additional data about the Alzheimer’s disease treatment it's developing with Biogen this week.
Editas (EDIT) faces a major setback as it decides to pause enrollment in the phase I/II BRILLIANCE study on EDIT-101, treating Leber congenital amaurosis type 10.
Spectrum (SPPI) gets a CRL from the FDA for poziotinib as the agency requires additional data. The company de-prioritized the poziotinib program.
Gilead and Arcus notched another win for their cancer program on Monday, pushing GILD stock briefly to a four-year high as RCUS stock gapped higher.
Until September, there was little reason to expect that the new treatment, called lecanemab, would work.
Is Pfizer stock a buy after surging on Moderna's omicron-focused booster shot data? Is PFE stock a buy right now?
Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP) (OTCQB: TBPMF) (FRA: JAM1), a leader in cannabinoid-derived drug discovery and development today announced the filing of three patent applications for its novel therapeutic, ARDS-003.
(Bloomberg) — Eisai Co shares fell the most in about 16 months following a report of a second death potentially linked to the groundbreaking experimental drug for Alzheimer’s disease it’s developing with Biogen Inc.Most Read from BloombergApple to Lose 6 Million iPhone Pros From Tumult at China PlantNext Covid-19 Strain May be More Dangerous, Lab Study ShowsMusk Threatens War With Apple, Jeopardizing Vital RelationshipStocks Hit by Fedspeak as China Woes Boost Havens: Markets WrapThe case invol
OPKO Health (OPK) is likely to gain from the potential in RAYALDEE that targets a growing market coupled with new collaborations and acquisitions.
Palforzia, the world’s only approved peanut allergy drug, has so far proved a flop, potentially because of a laborious treatment process.
Older adults need seven to nine hours of sleep per night just like other adults.
Novavax (NVAX) drops to record lows as the delayed product launch of its COVID-19 vaccine made it lose market share. Management slashes revenue guidance by more than half.
Public health authorities say Covid-19 vaccines are very effective at preventing severe illness and death, but a video watched more than 10 million times claims they are part of a depopulation conspiracy. Experts called the hour-long film "disinformation," pointing to multiple false claims, data showing millions of lives saved during the pandemic due to vaccination, and a lack of evidence supporting its assertions."Died Suddenly" was released November 21, 2022 on Rumble with the caption: "For ce
Rising interest rates and a looming recession that those higher rates could cause are weighing heavily on stock prices across the board. Shares of Biogen (NASDAQ: BIIB) have been on a roller coaster over the past couple of years. The stock rocketed higher in 2021 after the FDA granted a highly controversial approval to the company's Alzheimer's disease drug, Aduhelm.
Shares of CinCor Pharma Inc. fell 41.6% in premarket trading on Monday after the company said its experimental hypertension drug failed to meet the primary endpoint in a Phase 2 clinical trial. CinCor said it still plans to meet with the Food and Drug Administration in January to discuss plans for its Phase 3 program for baxdrostat. The company's stock is down 29.8% over the past three months, while the S&P 500 has declined 4.1%.
In a filthy alley behind a Los Angeles doughnut shop, Ryan Smith convulsed in the grips of a fentanyl high — lurching from moments of slumber to bouts of violent shivering on a warm summer day. When Brandice Josey, another homeless addict, bent down and blew a puff of fentanyl smoke his way in an act of charity, Smith sat up and slowly opened his lip to inhale the vapor as if it was the cure to his problems. The highly addictive and potentially lethal drug has become a scourge across America and is taking a toll on the growing number of people living on the streets of Los Angeles.
Cardiovascular disease remains the leading cause of death in the U.S., accounting for one in every five deaths each year. However, experts say there are many simple ways to reduce your risk of poor heart health—beginning with your morning routine. In particular, shuffling your schedule at the start of your day could make a significant impact on your cardiovascular health.Read on to learn how shifting one health habit to mid-morning could slash your risk of heart disease and stroke.READ THIS NEXT

source